Secretory leukocyte protease inhibitor is a proliferation and survival factor for pancreatic cancer cells

被引：11
|
作者：
Zuo, J. [1 ]
Zhang, C. [2 ]
Ren, C. [2 ]
Pang, D. [1 ]
Li, Y. [1 ]
Xie, X. [1 ]
Tang, Z. [1 ]
Jiang, X. [3 ]
机构：
[1] Cent S Univ, Xiangya Hosp, Dept Stomatol, Changsha 410008, Hunan, Peoples R China
[2] Cent S Univ, Canc Res Inst, Changsha 410078, Hunan, Peoples R China
[3] Cent S Univ, Xiangya Hosp, Dept Neurosurg, Changsha 410008, Hunan, Peoples R China
来源：
CLINICAL & TRANSLATIONAL ONCOLOGY | 2015年 / 17卷 / 04期
基金：
国家杰出青年科学基金;
关键词：
SLPI; Expression levels; shRNA; Pancreatic cancer; OVARIAN-CANCER; ANTI-PROTEASE; INFECTION; INFLAMMATION; EXPRESSION; RESPONSES;
D O I：
10.1007/s12094-014-1232-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A variety of inflammatory cytokines have been demonstrated to participate in tumorigenesis and progression. Secretory leukocyte protease inhibitor (SLPI) has been demonstrated to show a broad-spectrum of anti-inflammatory effects. This study investigates the expression of SLPI in human pancreatic cancer tissues and cells as well as its biological effects in human pancreatic cancer cells. Reverse transcription-polymerase chain reaction, immunohistochemistry, and Western blot were used to detect SLPI mRNA and protein levels in human pancreatic cancer tissues, adjacent tissues, and pancreatic cancer Bxpc-3 and Panc-1 cells. Knockout of SLPI expression was established by recombinant viral vector expressing short hairpin RNA (shRNA) targeting SLPI. Cell viability was analyzed by MTT assay. Cell apoptosis was detected by Hochest33258 staining and flow cytometry assay. Higher SLPI expression was observed in pancreatic tissues, Bxpc-3 cells, and Panc-1 cells compared to the peritumoral tissues (p < 0.01). SLPI expression in Bxpc-3 and Panc-1 cells was effectively silenced by shRNA (p < 0.001). Silencing of SLPI expression significantly reduced cell viability, inhibited cell proliferation, and induced cell apoptosis (p < 0.001). Abnormal over-expression of SLPI in pancreatic cancer cells may be associated with the development of disease through its roles in promoting cancer cell survival and proliferation as well as anti-apoptosis. SLPI can be used as a target for developing targeted therapy of pancreatic cancer.
引用
收藏
页码：314 / 321
页数：8
相关论文
共 50 条
  • [1] Secretory leukocyte protease inhibitor is a proliferation and survival factor for pancreatic cancer cells
    J. Zuo
    C. Zhang
    C. Ren
    D. Pang
    Y. Li
    X. Xie
    Z. Tang
    X. Jiang
    Clinical and Translational Oncology, 2015, 17 : 314 - 321
  • [2] The alarm anti-protease, secretory leukocyte protease inhibitor, is a proliferation and survival factor for ovarian cancer cells
    Simpkins, Fiona A.
    Devoogdt, Nick M.
    Rasool, Nabila
    Tchabo, Nana E.
    Alejandro, Emilyn U.
    Kamrava, Mitchell M. R. N.
    Kohn, Elise C.
    CARCINOGENESIS, 2008, 29 (03) : 466 - 472
  • [3] Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer
    D Zheng
    B Gui
    K P Gray
    I Tinay
    S Rafiei
    Q Huang
    C J Sweeney
    A S Kibel
    L Jia
    Oncogene, 2016, 35 : 4807 - 4815
  • [4] Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer
    Zheng, D.
    Gui, B.
    Gray, K. P.
    Tinay, I.
    Rafiei, S.
    Huang, Q.
    Sweeney, C. J.
    Kibel, A. S.
    Jia, L.
    ONCOGENE, 2016, 35 (36) : 4807 - 4815
  • [5] Secretory leukocyte protease inhibitor in cancer development
    Devoogdt, N
    Revets, H
    Ghassabeh, GH
    De Baetselier, P
    SIGNAL TRANSDUCTION AND COMMUNICATION IN CANCER CELLS, 2004, 1028 : 380 - 389
  • [6] Secretory Leukocyte Protease Inhibitor Antagonizes Paclitaxel in Ovarian Cancer Cells
    Rasool, Nabila
    LaRochelle, William
    Zhong, Haihong
    Ara, Gulshan
    Cohen, Joshua
    Kohn, Elise C.
    CLINICAL CANCER RESEARCH, 2010, 16 (02) : 600 - 609
  • [7] The production of secretory leukocyte protease inhibitor by dendritic cells
    Vroling, Aram B.
    Konijn, Tanja
    Samsom, Janneke N.
    Kraal, Georg
    MOLECULAR IMMUNOLOGY, 2011, 48 (04) : 630 - 636
  • [8] Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells
    Devoogdt, N
    Ghassabeh, GH
    Zhang, J
    Brys, L
    De Baetselier, P
    Revets, H
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (10) : 5778 - 5782
  • [9] Secretory leukocyte protease inhibitor (SLPI) promotes cancer by preventing degradation of the growth-and survival factor progranulin (PRGN)
    Devoogdt, Nick
    Rasool, Nabila
    Simpkins, Fiona
    Cohen, Joshua
    Tchabo, Nana
    Revets, Hilde
    Ghassabeh, Gholamreza Hassanzadeh
    Kohn, Elise
    De Baetselier, Patrick
    ACTA CLINICA BELGICA, 2008, 63 (01): : 48 - 48
  • [10] Overexpression of a secretory leukocyte protease inhibitor in human gastric cancer
    Cheng, Wan-Li
    Wan, Chia-Siu
    Huang, Ya-Hui
    Liang, Ying
    Lin, Paul Y.
    Hsueh, Chuen
    Wu, Yi-Chin
    Chen, Wei-Jan
    Yu, Chia-Jung
    Lin, Sheue-Rong
    Lin, Kwang-Huei
    INTERNATIONAL JOURNAL OF CANCER, 2008, 123 (08) : 1787 - 1796
12345